Compile Data Set for Download or QSAR
maximum 50k data
Found 1692 with Last Name = 'ahn' and Initial = 'dr'
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296480(CHEMBL553249)
Affinity DataKi:  3.40E+3nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296473(CHEMBL558940)
Affinity DataKi:  3.70E+3nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296481(CHEMBL562618)
Affinity DataKi:  5.80E+3nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296477(CHEMBL563460)
Affinity DataKi:  1.30E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296478(CHEMBL557433)
Affinity DataKi:  1.50E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296476(CHEMBL557420)
Affinity DataKi:  1.60E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296479(CHEMBL562806)
Affinity DataKi:  1.80E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296475(CHEMBL557344)
Affinity DataKi:  5.00E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296474(CHEMBL558009)
Affinity DataKi:  5.80E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296482(CHEMBL541769)
Affinity DataKi:  7.70E+4nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296483(CHEMBL538372)
Affinity DataKi:  1.09E+5nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHypoxia-inducible factor 1-alpha(Homo sapiens (Human))
Institute Of Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296472(CHEMBL558824)
Affinity DataKi: >5.00E+5nMAssay Description:Inhibition of interaction between fluorescein-labeled proline hydroxylated human HIFalpha (556 to 575) and human VHL-human elongin B-human elongin C ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617349(US20230279025, Example 465)
Affinity DataIC50:  0.00100nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617355(US20230279025, Example 468)
Affinity DataIC50: <0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579601(CHEMBL4858364 | US11453683, Example 252 | US202302...)
Affinity DataIC50: <0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617323(US20230279025, Example 452 | US20230279025, Exampl...)
Affinity DataIC50: <0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617363(US20230279025, Example 482)
Affinity DataIC50: <0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617357(US20230279025, Example 469)
Affinity DataIC50: <0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573400(US11453683, Example 259 | US20230279025, Example 4...)
Affinity DataIC50: <0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617351(US20230279025, Example 466)
Affinity DataIC50:  0.00600nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617347(US20230279025, Example 464)
Affinity DataIC50:  0.00700nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617345(US20230279025, Example 463)
Affinity DataIC50:  0.0120nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM617339(US20230279025, Example 460)
Affinity DataIC50:  0.0270nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM616938(US20230279025, Example 26 | US20230279025, Example...)
Affinity DataIC50:  0.0620nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573426(US11453683, Example 284 | US20230279025, Example 2...)
Affinity DataIC50:  0.100nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573426(US11453683, Example 284 | US20230279025, Example 2...)
Affinity DataIC50:  0.100nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579600(CHEMBL4857438 | US11453683, Example 251 | US202302...)
Affinity DataIC50:  0.200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579600(CHEMBL4857438 | US11453683, Example 251 | US202302...)
Affinity DataIC50:  0.200nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579595(CHEMBL4863339 | US11453683, Example 185 | US202302...)
Affinity DataIC50:  0.300nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579595(CHEMBL4863339 | US11453683, Example 185 | US202302...)
Affinity DataIC50:  0.300nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM565148(US11414404, Ex. # 25 | US11634409, Example 25)
Affinity DataIC50:  0.340nMAssay Description:A competitive displacement assay was configured for B-Raf that monitors the amount of a fluorescently-tagged “tracer” bound to B-Raf via TR-FRET from...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM565148(US11414404, Ex. # 25 | US11634409, Example 25)
Affinity DataIC50:  0.340nMAssay Description:A competitive displacement assay was configured for B-Raf that monitors the amount of a fluorescently-tagged “tracer” bound to B-Raf via TR-FRET from...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573644(US11453683, Example 439 | US20230279025, Example 4...)
Affinity DataIC50:  0.400nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579594(CHEMBL4859236 | US11453683, Example 36 | US2023027...)
Affinity DataIC50:  0.400nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573644(US11453683, Example 439 | US20230279025, Example 4...)
Affinity DataIC50:  0.400nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579594(CHEMBL4859236 | US11453683, Example 36 | US2023027...)
Affinity DataIC50:  0.400nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573484(US11453683, Example 340 | US20230279025, Example 3...)
Affinity DataIC50:  0.400nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579601(CHEMBL4858364 | US11453683, Example 252 | US202302...)
Affinity DataIC50:  0.400nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579601(CHEMBL4858364 | US11453683, Example 252 | US202302...)
Affinity DataIC50:  0.400nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579597(CHEMBL4876040 | US11453683, Example 243 | US202302...)
Affinity DataIC50:  0.400nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573433(US11453683, Example 63 | US20230279025, Example 63)
Affinity DataIC50:  0.400nMAssay Description:Table 2: The ability of a compound to bind to KRAS G12D was measured using a TR-FRET displacement assay. Biotinylated GDP-loaded recombinant human KR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579597(CHEMBL4876040 | US11453683, Example 243 | US202302...)
Affinity DataIC50:  0.400nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573433(US11453683, Example 63 | US20230279025, Example 63)
Affinity DataIC50:  0.400nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573484(US11453683, Example 340 | US20230279025, Example 3...)
Affinity DataIC50:  0.400nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM565192(US11414404, Ex. # 69 | US11634409, Example 69)
Affinity DataIC50:  0.460nMAssay Description:A competitive displacement assay was configured for B-Raf that monitors the amount of a fluorescently-tagged “tracer” bound to B-Raf via TR-FRET from...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM565192(US11414404, Ex. # 69 | US11634409, Example 69)
Affinity DataIC50:  0.460nMAssay Description:A competitive displacement assay was configured for B-Raf that monitors the amount of a fluorescently-tagged “tracer” bound to B-Raf via TR-FRET from...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573647(US11453683, Example 441 | US20230279025, Example 4...)
Affinity DataIC50:  0.5nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573424(US11453683, Example 282 | US11453683, Example 366 ...)
Affinity DataIC50:  0.5nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM50579598(CHEMBL4857719 | US11453683, Example 245 | US202302...)
Affinity DataIC50:  0.5nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGTPase KRas [G12D](Homo sapiens (Human))
Mirati Therapeutics

US Patent
LigandPNGBDBM573598(US11453683, Example 189 | US20230279025, Example 1...)
Affinity DataIC50:  0.5nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
Displayed 1 to 50 (of 1692 total ) | Next | Last >>
Jump to: